Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based study
Abstract Background Although thyroid cancer is associated with low mortality rates, significant racial disparities in thyroid cancer outcomes have not been adequately studied in Asia. Moreover, the Asian population consists of different ethnic groups that are not homogeneous. This study aimed to per...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13211-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559405993132032 |
|---|---|
| author | Haiyun Liu Shuxia Zhang Xiaohui Liu Qianqian Wang Hongjie Zhang Weihong Cui |
| author_facet | Haiyun Liu Shuxia Zhang Xiaohui Liu Qianqian Wang Hongjie Zhang Weihong Cui |
| author_sort | Haiyun Liu |
| collection | DOAJ |
| description | Abstract Background Although thyroid cancer is associated with low mortality rates, significant racial disparities in thyroid cancer outcomes have not been adequately studied in Asia. Moreover, the Asian population consists of different ethnic groups that are not homogeneous. This study aimed to perform a population-based analysis of survival outcomes and prognostic factors in thyroid cancer patients. Methods The demographic data and tumor characteristics of all the thyroid cancer patients identified were obtained from the Yantai Cancer Registry. The thyroid cancer-specific death risk in patients was evaluated using the proportion of deaths, standardized mortality ratio (SMR) and absolute excess risk (AER). The Kaplan‒Meier method and the Cox proportional hazards regression model were used to evaluate overall survival (OS) and prognosis. Results A total of 10,852 new cases of thyroid cancer occurred with a 5-year OS of 96.20% in Yantai from 2012 to 2022. The SMR decreased from 1.06 (95%CI: 0.93 − 1.33) in 2012 to 0.50 (95%CI: 0.42 − 0.63) in 2022 and the AER decreased from 11.07 (95%CI: -13.42 − 47.39) per 10,000 population in 2012 to -105.02 (95%CI: -149.53 − -63.02) per 10,000 population in 2022. Disparities in the OS of thyroid cancer patients were found across different diagnosis periods, genders, age groups, places of residence, occupational classes, tumor sites and sizes, cervical lymph node metastasis statuses, TgAb levels, pathological types, clinical stages and treatment timings (all p < 0.05). Multivariate analysis showed that age group (≥ 65 years: HR = 1.727), tumor site (location in the isthmus: HR = 3.117), tumor size (> 3 cm: HR = 3.170), cervival lymph node metastasis (HR = 1.876), TgAb levels (115 − 500 IU/ml: HR = 7.103; > 500 IU/ml: HR = 13.554), pathological types (MTC: HR = 2.060; ATC: HR = 10.747), clinical stages (stage II: HR = 2.224; stage III: HR = 3.361; stage IV: HR = 3.494), treatment timing (> 3 months: HR = 2.594), diagnosis period (2017 − 2022: HR = 0.633) and gender (female: HR = 0.711) were found to be associated with the risk of death; after stratified adjustment, significant differences in prognostic factors were identified among thyroid cancer patients with varying pathological types. Conclusion The risk of death from thyroid cancer in Yantai has significantly decreased and the OS of patients has improved significantly in the past decade. The prognosis of thyroid cancer in this area was notably impacted by various factors and the resolution of survival study outcomes for thyroid cancer patients should be enhanced. |
| format | Article |
| id | doaj-art-fd117c68f03547688d1bb76a8b44a48c |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-fd117c68f03547688d1bb76a8b44a48c2025-01-05T12:33:11ZengBMCBMC Cancer1471-24072024-12-0124111110.1186/s12885-024-13211-8Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based studyHaiyun Liu0Shuxia Zhang1Xiaohui Liu2Qianqian Wang3Hongjie Zhang4Weihong Cui5Department of Medicine, Shandong College of Traditional Chinese MedicineQixia City People’s HospitalQingdao Institute of Prevention Medicine, Qingdao Center for Disease Control and PreventionYantai Center for Disease Control and PreventionYantai Center for Disease Control and PreventionDepartment of Medicine, Shandong College of Traditional Chinese MedicineAbstract Background Although thyroid cancer is associated with low mortality rates, significant racial disparities in thyroid cancer outcomes have not been adequately studied in Asia. Moreover, the Asian population consists of different ethnic groups that are not homogeneous. This study aimed to perform a population-based analysis of survival outcomes and prognostic factors in thyroid cancer patients. Methods The demographic data and tumor characteristics of all the thyroid cancer patients identified were obtained from the Yantai Cancer Registry. The thyroid cancer-specific death risk in patients was evaluated using the proportion of deaths, standardized mortality ratio (SMR) and absolute excess risk (AER). The Kaplan‒Meier method and the Cox proportional hazards regression model were used to evaluate overall survival (OS) and prognosis. Results A total of 10,852 new cases of thyroid cancer occurred with a 5-year OS of 96.20% in Yantai from 2012 to 2022. The SMR decreased from 1.06 (95%CI: 0.93 − 1.33) in 2012 to 0.50 (95%CI: 0.42 − 0.63) in 2022 and the AER decreased from 11.07 (95%CI: -13.42 − 47.39) per 10,000 population in 2012 to -105.02 (95%CI: -149.53 − -63.02) per 10,000 population in 2022. Disparities in the OS of thyroid cancer patients were found across different diagnosis periods, genders, age groups, places of residence, occupational classes, tumor sites and sizes, cervical lymph node metastasis statuses, TgAb levels, pathological types, clinical stages and treatment timings (all p < 0.05). Multivariate analysis showed that age group (≥ 65 years: HR = 1.727), tumor site (location in the isthmus: HR = 3.117), tumor size (> 3 cm: HR = 3.170), cervival lymph node metastasis (HR = 1.876), TgAb levels (115 − 500 IU/ml: HR = 7.103; > 500 IU/ml: HR = 13.554), pathological types (MTC: HR = 2.060; ATC: HR = 10.747), clinical stages (stage II: HR = 2.224; stage III: HR = 3.361; stage IV: HR = 3.494), treatment timing (> 3 months: HR = 2.594), diagnosis period (2017 − 2022: HR = 0.633) and gender (female: HR = 0.711) were found to be associated with the risk of death; after stratified adjustment, significant differences in prognostic factors were identified among thyroid cancer patients with varying pathological types. Conclusion The risk of death from thyroid cancer in Yantai has significantly decreased and the OS of patients has improved significantly in the past decade. The prognosis of thyroid cancer in this area was notably impacted by various factors and the resolution of survival study outcomes for thyroid cancer patients should be enhanced.https://doi.org/10.1186/s12885-024-13211-8Thyroid cancerPopulation-basedOverall survivalPrognostic factors |
| spellingShingle | Haiyun Liu Shuxia Zhang Xiaohui Liu Qianqian Wang Hongjie Zhang Weihong Cui Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based study BMC Cancer Thyroid cancer Population-based Overall survival Prognostic factors |
| title | Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based study |
| title_full | Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based study |
| title_fullStr | Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based study |
| title_full_unstemmed | Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based study |
| title_short | Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based study |
| title_sort | thyroid cancer survival and prognostic factors in yantai china 2012 2022 a population based study |
| topic | Thyroid cancer Population-based Overall survival Prognostic factors |
| url | https://doi.org/10.1186/s12885-024-13211-8 |
| work_keys_str_mv | AT haiyunliu thyroidcancersurvivalandprognosticfactorsinyantaichina20122022apopulationbasedstudy AT shuxiazhang thyroidcancersurvivalandprognosticfactorsinyantaichina20122022apopulationbasedstudy AT xiaohuiliu thyroidcancersurvivalandprognosticfactorsinyantaichina20122022apopulationbasedstudy AT qianqianwang thyroidcancersurvivalandprognosticfactorsinyantaichina20122022apopulationbasedstudy AT hongjiezhang thyroidcancersurvivalandprognosticfactorsinyantaichina20122022apopulationbasedstudy AT weihongcui thyroidcancersurvivalandprognosticfactorsinyantaichina20122022apopulationbasedstudy |